Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DRY POWDER PHARMACEUTICAL COMPOSITION FOR NASAL INSTILLATION
Document Type and Number:
WIPO Patent Application WO/2019/021957
Kind Code:
A1
Abstract:
There has been developed an influenza vaccine nasal instillation powder formulation that can be stored at room temperature and can deliver a given amount of antigen directly to a target site (nasal turbinates, nasopharynx) by nasal inoculation. A nasal instillation powder formulation containing an influenza vaccine antigen (component 1), a pharmacologically acceptable saccharide or polyol (component 2), and a pharmacologically acceptable additive that is neither water-soluble nor hygroscopic (component 3).

Inventors:
INOUE KAZUHIRO (JP)
TSUTSUMI YASUHIRO (JP)
TANIMOTO MITSUHIDE (JP)
NAKAMURA SHOGO (JP)
SHINODA KAORI (JP)
Application Number:
JP2018/027266
Publication Date:
January 31, 2019
Filing Date:
July 20, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
DAIICHI SANKYO CO LTD (JP)
International Classes:
A61K39/145; A61K9/14; A61K47/04; A61K47/10; A61K47/12; A61K47/18; A61K47/26; A61K47/38; A61P31/16
Domestic Patent References:
WO2017090767A12017-06-01
Foreign References:
JP2013523602A2013-06-17
JP2013515748A2013-05-09
JP2005532987A2005-11-04
JP2015091791A2015-05-14
JPH09227373A1997-09-02
JPS632932A1988-01-07
Other References:
NAGAI, TAKAYUKI ET AL.: "Enhancement of in vivo anti-influenza virus activity of 5,7,4-trihydroxy-8-methoxyflavone by drug delivery system using hydroxypropyl cellulose", BIOL. PHARM. BULL., vol. 20, no. 10, 1 January 1997 (1997-01-01), pages 1082 - 1085, XP055678292, ISBN: 1347-5215, DOI: 10.1248/bpb.20.1082
Attorney, Agent or Firm:
ISHIBASHI Koki et al. (JP)
Download PDF: